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The development of health policy in Malawi:
The  influence of context, evidence and links in 
the creation of a national policy for cotrimoxazole 
prophylaxis
   Abstract
Within the health policy field, a growing literature is attempting to 
understand the diverse responses of policy makers to research, and to 
explain why certain research findings make their way into policy while 
others are effectively ignored. In this paper we apply a policy analysis 
framework to the development of cotrimoxazole prophylaxis national 
policy in Malawi. Arguing that Malawi was one of the early adopters of 
cotrimoxazole prophylaxis at a national level, we show how the research to 
policy process was influenced by national healthcare context, the networks 
of individuals involved, and the nature of the public health evidence itself.
Introduction
Cotrimoxazole (CTX) is an antimicrobial drug that has 
been used as a prophylaxis against HIV related infection 
in Europe and North America since the early 1990s1. In 
1999, two randomised controlled trials, demonstrated that 
cotrimoxazole prophylaxis (CPT) reduced morbidity for 
adults with HIV, and reduced morbidity and mortality for 
HIV positive adults co-infected with tuberculosis (TB) in 
Cote d’Ivoire2-3. In 2000, the World Health Organization 
(WHO) and United Nations AIDS Programme (UNAIDS) 
responded by releasing provisional recommendations that 
CPT be scaled up across Africa for HIV positive adults and 
children2-4. In 2004, the results of  a trial on the efficacy of  
CPT for HIV positive children in Zambia demonstrated that 
CPT significantly reduced morbidity and mortality among 
children of  all ages, at different stages of  disease progression, 
and the effect was sustained beyond 12 months of  use5. This 
resulted in a set of  international paediatric recommendations 
that CPT be given to HIV infected and exposed children 
in Africa6. Finally, and at least in part in reaction to the 
recognition that scale-up of  CPT was extremely slow across 
the continent, the WHO issued detailed guidelines on the 
use of  CPT in resource poor settings in 2006 for both adults 
and children1.
Despite these international recommendations, concerns 
have been raised that routine use of  CPT has only partially 
been translated into practice7-9. Since 2007, three papers have 
been published which question why it has taken so long for 
CPT to be implemented in resource-limited settings, and 
questions remain as to why policy making around CPT in 
these settings has varied, in terms of  time taken to reach 
a decision on its implementation, and the content of  the 
national policies7-9.
To understand this variation in timing and policy content, we 
conducted a three country study comparing national policy 
processes for CPT (across Malawi, Uganda and Zambia) 
focusing on the ways in which national context impacts on 
health policy making. This paper examines the findings of  
the Malawi study, and focuses on the creation of  two sets 
of  national policy on CPT in Malawi: the use of  CPT for 
HIV positive TB patients in 2002, and the second, more 
general policy on the use of  CPT for HIV positive adults 
and children in 2005. The paper explores the ways in which 
the Malawian national policy development process for CPT 
was shaped by the healthcare context, the links between 
researchers and policy makers, and the evidence available.
It presents the model that we used and the methods 
employed before turning to consider our empirical evidence 
in two sections. The first section relates to the 2002 policy 
which was formed by the National Tuberculosis Control 
Programme (NTP) of  the Ministry of  Health and Population 
(MOHP), and the second relating to the 2005 policy 
which was formed by the HIV. Unit of  MOHP. The data 
demonstrate the importance of  having a favourable policy 
context, but show how concerns about the power of  the 
evidence available can be mitigated by the links and actions 
of  a policy entrepreneur – a key actor who supports a policy 
change and who is strategically connected to research and 
policy making networks. Conversely, the data shows that 
when the evidence base is exceptionally strong, there is less 
of  a need for such an entrepreneurial role by policy actors.
Methods
The field of  policy analysis has shown that the ideal model 
of  policy making in which research evidence is expected to 
follow a direct path into policy formation rarely exists in 
reality.
Recognising this, a number of  frameworks and theories have 
been put forward to enable an analysis of  what drives and 
shapes national and international policy process, looking in 
particular at the influence of  political, economic and social 
context10-12. The majority of  these frameworks have focused 
on policy making in high income countries, but over the last 
ten years a number of  analysts have sought to understand 
the particular issues pertaining to policy making in resource 
poor settings13-14.
Walt and Gilson argue that the analysis of  health policy in 
developing countries has been dominated by a consideration 
of  the technical content of  the policy, with little emphasis 
on understanding the central influence that policy actors, 
context and process have on policy formation14. In their 
model they posit that policy actors negotiate context, 
content and process in order to realise policy change, and 
that these factors should be mapped to enable a detailed 
understanding of  health policy development14. Crewe 
and Young present a framework to understand the uptake 
of  research into policy, which sees policy formation as a 
function of  the interaction between: context (including local 
politics as well as the formal policy making institutions in a 
country), evidence (seen to reflect the credibility of  evidence 
and communication of  it) and links (seen to encompass the 
influence and legitimacy of  key actors presenting research 
findings)13. Developing this framework further, Court and 
Young stress the importance of  considering influences which 
are apparently beyond the national context when focusing 
on the case of  developing countries15. In particular they 
point to the impact that international political agreements 
and policy; donor development policies; and donor research 
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and funding have on policy creation and implementation15. 
Both Crewe and Young and Court and Young conceptualise 
context, evidence and links as having overlapping elements.
For the purposes of  our research we combined the analysis 
of  context, evidence and links with Walt and Gilson’s focus 
on the policy process as a dynamic concept. Importantly 
we also considered the relationships between the elements 
of  the framework. Context, for instance, is conceptualised 
as having overarching impact on all other aspects. Within 
the context, policy actors interact with evidence (producing 
and/or interpreting it; accepting or rejecting it), while the 
links between policy actors shape the way in which evidence 
is made available and responded to. Diagrammatically our 
framework is represented in Figure 1:
This exploration of  the research to policy process for CPT 
in Malawi was conducted as a case study. Published and 
unpublished documents relating to efficacy, evidence and 
national policies were reviewed. This was supplemented 
with in-depth interviews carried out with fifteen local policy 
makers. Initial key informants were selected from previously 
identified influential policy bodies, and snowball sampling 
methods were used to identify further actors who were 
involved in, and linked to the policy process around CPT. 
Interviews were conducted via telephone,recorded and then 
transcribed by the lead researcher (EH), with data analysis 
facilitated through the use of  the Nvivo qualitative analysis 
software package. Ethical clearance was obtained from the 
London School of  Hygiene and Tropical Medicine, and the 
Malawi National Health Sciences Research Committee.
Results
Evidence for the policy development process
Much of  the Malawian research conducted on the efficacy 
and feasibility of  introducing CPT addressed CPT as a 
potential intervention for HIV positive tuberculosis patients 
and was conducted in collaboration with the National 
Tuberculosis Programme (NTP). In 1999, when the results 
of  the research from Cote d’Ivoire were published, concerns 
about their generalisability across Africa were raised by senior 
Malawian researchers in a letter to the Lancet 2-3 16-17. At this 
stage, a Malawian randomised controlled trial conducted by 
the College of  Medicine (COM) examining the benefits of  
CPT for HIV infected TB patients was in its infancy. The 
letter warned of  high rates of  bacterial resistance to CTX 
in Malawi in comparison to Abidjan, and the potential that 
widespread use of  CTX as a prophylaxis might increase 
resistance to Malawi’s first line malaria treatment16.
Despite these concerns, funding by UNAIDS for the 
Malawian trial was halted, and in 2000, the publication 
of  WHO recommendations (based on the Abidjan data) 
resulted in the Malawi government considering that placebo 
controlled trials on the efficacy of  CPT were no longer 
ethical17-18. The government maintained, however, that the 
evidence base for the WHO’s recommendations from 2000 
was not powerful enough to warrant the implementation of  
CPT within the country18.
Although the initial Malawian trial had been halted, research 
into the efficacy of  CPT for HIV positive TB patients 
continued. The COM adapted their trial to analyse efficacy 
of  two different doses of  CTX in HIV positive patients 
with TB and then compared these with historical controls17. 
Two further projects examining efficacy and feasibility were 
conducted in collaboration with the NTP, one in Karonga 
in the north of  the country, and one in Thyolo in the 
south18-19. The results of  these studies were released in 2002 
demonstrating that CPT reduced mortality among HIV 
positive TB patients, and supporting the implementation of  
CPT for HIV positive TB patients. During the same year 
the ProTEST initiative1, which had piloted the provision 
CPT for HIV positive TB patients within Lilongwe District, 
reported their findings that it was feasible to provide CPT 
for this group of  patients20. That year, government approved 
a national policy of  providing adjunctive CPT for HIV 
positive TB patients during and following their TB
treatment21. The Malawi 2002 policy specifically 
recommended that:
• TB patients who test seropositive for HIV will be offered 
cotrimoxazole for the duration of  anti-TB treatment (i.e. 8 
months).
• Patients should continue to take cotrimoxazole once they 
have completed the TB treatment, but the procurement, 
distribution, supervision and monitoring of  CTX treatment 
post TB treatment would not be the responsibility of  the 
NTP.
Following the publication of  the policy, two further, smaller 
pieces of  research demonstrated that the provision of  CPT 
for HIV positive TB patients could be scaled up and was 
associated with good treatment outcomes in Malawi22-23. 
In addition, a further study examining the incidence of  
CTX preventable infections in HIV positive adults in 
Blantyre found high levels of  malaria and invasive bacterial 
infections24.
Between 2004 and 2005 studies from Zambia, South Africa 
and Uganda provided evidence that:
CPT reduced morbidity and mortality (among HIV positive 
children) in areas of  high bacterial resistance to CTX 
(Zambia); CPT may help to reduce mortality in individuals 
with TB in an area of  high HIV prevalence (South Africa); 
and that daily CPT was associated with reduced morbidity 
and mortality and had beneficial effects on CD4-cell count 
and viral load (Uganda)5,25-26. This prompted the HIV Unit 
at the Ministry of  Health to adopt a broader national CPT 
policy27 (MKI 2:27/01/09).
The 2005 Malawi national policy was then written, specifically 
recommending the following:
• CPT should be offered to HIV-positive adults (aged 15 
years and above) in stages II, III
or IV of  HIV disease; all people with a CD4 count of  
500mm3 or less (regardless of  symptoms); pregnant women 
after the first trimester who fall into one or both of  the 
previous two categories. CPT prophylaxis should be taken 
for life, even if  the patient is taking ARVs.
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• CTX should be offered to children aged 6 weeks or above, 
born to an HIV-positive woman (irrespective of  whether the 
woman received antiretroviral therapy in pregnancy) until 
HIV can be confidently excluded; any child of  6 weeks or 
more who is HIV-positive
regardless of  symptoms. CPT prophylaxis should be taken 
for life, even if  the patient is taking ARVs27.
The 2002 Policy Processes
While the above provides the description of  the policy 
content, as well as the development of  the body of  evidence 
and the overall timeline, it does not explain why or how 
particular processes were followed, or why Malawi was so 
swift in its development of  the 2002 policy. In order to 
explain the use and uptake of  research evidence in Malawi, 
the following section of  this paper examines the influence 
of  national context, the nature of  the evidence, and the links 
between key
actors.
Context
Interviews conducted identified three elements of  the existing 
political context as particularly important in influencing how 
the 2002 policy process unfolded: the history of  HIV and 
AIDS programming in Malawi, the established role of  the 
National TB Control Programme, and the existing issues 
facing the national Malaria Control Programme. In terms of  
national HIV and AIDS programming, the national response 
to HIV and AIDS was initially (from 1988) coordinated by 
the National AIDS Control Programme (NACP), established 
at the Ministry of  Health and Population (MOHP)28. From 
its initiation through the 1990s, attention was primarily paid 
to prevention rather than treating those who were already 
infected.
According to one interviewee:
“The HIV programme did not have any say on 
cotrimoxazole, and they didn’t have any strong views. 
I do remember that at that time the HIV programme 
was emphasising HIV prevention…. but without 
offering them any medication ……. they had other 
priorities and so this is what we saw from the HIV 
programme, it was more about the preventive aspect, 
use of condoms and safe blood. (MKI 12/11/ 2009)
In 2001, the National AIDS Control Programme was 
transformed into the National AIDS Commission,(NAC)
and later moved from MOHP to the Office of  the President 
and Cabinet.
While an HIV Unit at the MOHP was in existence, staffing 
was reduced to one official (until 2003/2004 see below). 
Many of  the HIV AIDS programming activities were 
therefore undertaken by the NAC, institution which had a 
multi-sectoral national role rather than a medical focus (MKI 
10:20,02,09) 
In contrast to HIV and AIDS Programming in Malawi, 
the NTP had long term key characteristics that made it a 
highly favourable environment for CTX research, policy 
making and implementation. The NTP had a much longer 
history (running since 1964) and was a well funded (receiving 
support from several donor agencies), and well established 
programme with a treatment orientation for TB patients, 
of  whom it was estimated in 2001, 70% were co-infected 
with HIV (MKI1, MKI6)2,30. The high mortality rates among 
HIV positive TB patients were of  great concern to those 
within the NTP. Furthermore, the pilot ProTEST project 
was being run in collaboration with the NTP, and it had a 
particular interest in establishing joint TB/HIV integrated 
services. Finally, part of  the NTP’s budget was set aside 
for operational research, which was highly valued by those 
working within the programme in providing evidence to 
influence national policy and address programmatic issues. 
As will be shown, this proved particularly important for CPT 
research and policy development3.
The final key political contextual element identified as 
important was the concerns of  the existing national Malaria 
Control Programme. The Malaria programme was particularly 
concerned about the chemical interaction between CTX and 
Sulfadoxine/Pyrimethamine (SP).
They considered that widespread use of  CTX would generate 
resistance to SP, which was the first line drug for Malaria 
treatment at the time.
Evidence
The above contextual factors set the stage in which CPT 
evidence was developed and understood. The second element 
of  our conceptual framework was to look at the nature of  the 
evidence itself, and how it is understood, to explain its use in 
policy formulation. As mentioned, the weight of  the evidence 
behind the WHO/UNAIDS provisional recommendations 
on CPT of  2000 was enough to lead to the halting of  the 
randomised controlled trial which was underway in Blantyre, 
yet the Government of  Malawi did not see the evidence as 
definitive enough for areas with high bacterial resistance to 
CTX and different disease burdens to Cote d’Ivoire17,22. The 
publication of  international recommendations based on 
evidence from Cote d’Ivoire alone was considered by some 
medical researchers to have had hindered national policy 
development. As one interviewee explained:
You should go back to 2000, the letter written [by Malawian 
researchers] to the Lancet.
It said that this was completely, the wrong decision of  
UNAIDS, because there were studies going on in Malawi, 
Cape Town, and Senegal. All three of  those studies 
stopped..… I think that UNAIDS held up the implementation 
of  CPT in Africa … we said that we cannot use the Cote 
d’Ivoire evidence, we don’t have toxoplasmosis, or we didn’t 
think that we had toxoplasmosis; and the resistance rates are 
different.. (MKI 2).
Other research, however, was soon to be conducted which 
was seen to have much more immediate national relevance. 
Three new studies began in Malawi specifically looking at 
CPT for HIV positive TB patients starting between 1999 and 
2000. One was the re-designed trial comparing the efficacy 
of  two different doses of  CPT to historical controls, while 
the other two were operational cohort studies conducted 
simultaneously and in collaboration with the NTP.
The operational nature of  this work meant that the potential 
for the research results to have local policy relevance was 
established before the research began. In addition, under the 
ProTEST pilot project, the feasibility of  implementing CPT 
for HIV positive TB patients was examined.
However, the fact that the research was produced locally and 
was of  policy relevance did not mean that it was accepted 
by all of  the local actors. During the policy meeting which 
led to the 2002 policy, three concerns were raised about 
the evidence base: the strength of  the operational research 
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given the use of  historical controls; the lack of  evidence on 
whether widespread use of  CTX would increase resistance 
to SP, and the lack of  evidence as to whether CTX would be 
needed if  anti-retroviral therapy became available21, 4.
Links
The final element of  the framework used to explain policy 
change is to understand the key roles played by networks 
of  actors (or groups of  actors) and the links between them. 
Two key,sometimes overlapping, networks were identified: 
researchers (involved in the local CPT research from 
the College of  Medicine in Blantyre), and policy makers 
(from the MOHP’s HIV Unit, NTP and Malaria control 
programme). Within the national context, and when there 
is uncertainty about international and national evidence, key 
actors are often needed to mobilise opinion or push policy 
change forward. Interviews identified one key individual a 
‘policy entrepreneur’ (identified by 11 of  the 15 interviewees) 
whose actions were critical to taking the policy forward. In 
addition a group of  ‘policy champions’ (actors particularly 
motivated about an issue with power or authority to lend to 
it) who surrounded him were also identified. This individual 
and the supporting network were able to use their links and 
influence to overcome lingering concerns about the evidence 
of  CPT, and to identify the policy channels needed to finally 
establish the 2002 component of  the national policy.The 
strategic position of  the policy entrepreneur arose from his 
background as a medical researcher as well as a programme 
officer. One informant explained that the policy entrepreneur 
involved senior MOHP personnel in the discussions about 
CPT very early in the process, explaining: (MKI 12). …. the 
TB programme had prioritised its own research, it made sure 
that there was a coownership process among the stakeholders 
…… I personally think that this is a key step when we run 
operational research to facilitate policy transfer. It was very 
different when someone from an academic institution goes 
to the MOH and says here is a study here are the results and 
would you like to implement it (MKI 12).
Entrepreneurs cannot bring about change on their own, 
however. They link important networks and groups, or 
identify key contextual features providing opportunities 
for change, but policy change is ultimately still driven by 
interests and groups with power. In this case, while the 
policy entrepreneur was certainly central to driving the 
policy process forward, he was also surrounded by several 
supportive policy champions, including senior researchers 
involved in local CPT studies and senior members of  staff  at 
the NTP – a group with the power and legitimacy to provide 
support for policy change. The importance of  this group and 
their links finally cuminated in the 2002 meeting that lead 
to the first national CPT policy. As discussed above, there 
were concerns about the strength of  the evidence base. Yet 
the local researchers (the policy champions), were passionate 
about their results, defending their research model when its 
validity was questioned. 
The 2005 policy process
The above text details the elements of  the conceptual 
framework which were seen to explain the uptake of  
research into policy in 2002. However, by 2005, a second, 
broader national CPT policy had been developed. Our 
analysis found that the same conceptual elements were 
important to explaining this second policy development 
process, yet the details of  each element had changed. The 
field of  policy analysis recognises that policy development 
is a dynamic and social process. Over time, shifts within 
the national and internationa healthcare context and in the 
body of  international evidence available, reshaped the policy 
environment. 
Context
Between 2003 and 2004, there was an increasing attention 
paid to biomedical interventions for HIV treatment. The 
HIV Unit in the Ministry of  Health was established with four 
(senior) members of  staff  recruited (MKI10:20,02,09), and 
a national plan for anti-retroviral therapy in the public sector 
was developed in 2004 (with financial support from The 
Global Fund to Fight AIDS, Tuberculosis and Malaria)32. In 
addition, the national Malaria Control Programme agreed to 
phase out SP use for first-line treatment for uncomplicated 
Malaria. While it remained in use for intermittent presumptive 
therapy in pregnancy and people living in remote areas 
where it is difficult to access ACT, this shift in Malaria policy 
meant that concerns about cross resistance were not longer 
so profound.
Evidence
By 2005 there had been an increase in evidence on the 
efficacy of  CPT for HIV related opportunistic infection. 
Of  very high significance were the results of  a paediatric 
randomised control trial in Zambia, which demonstrated 
that CPT reduced mortality by 43% and hospitalisation by 
23% in HIV positive children in an area with high bacterial 
in-vitro resistance to CTX 5. Research from South Africa, 
with similarly high rates of  bacterial resistance to CTX, 
concurred with the Malawian results showing a reduction in 
mortality among TB patients taking CPT in an area with high 
HIV prevalence25. In Uganda, research results showed that 
CPT was associated with reduced morbidity and mortality, 
had a beneficial effect on CD4 cell count and viral load 
among HIV positive adults, again in an area of  high bacterial 
resistance to CTX 26. Further, a study on the incidence of  
CTX preventable infections in HIV positive adults in Malawi 
demonstrated that these patients had high levels of  malaria 
and invasive bacterial infections24. Given the weight of  the 
new evidence base, the discussions surrounding the evidence 
for a new broader CPT policy in 2005 were reported by 
interviewees to have been much less contentious than those 
in 2002.
Links
In 2004, as the HIV Unit at the MOHP was developed, four 
new members of  staff  were recruited to begin the scale up of  
the treatment and care programme. The policy entrepreneur 
from the TB programme, who had been highly influential 
for the 2002 policy, was recruited into the HIV Unit, and 
began to organise meetings to prepare for a more general 
CPT policy. His role in the policy development process in 
2005 was, however, quite different. Whereas before he had 
been central in gathering support for CPT, ensuring local 
ownership and bridging the policy and research networks, 
in 2005 he was central in driving forward meetings, and, 
following MOHP endorsement, and making sure that the 
policy was written. None of  the informants identified the 
former policy champions as needing to play an advocacy role 
in the development of  the 2005 policy process.
Discussion
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The insights to be gained from critical analysis of  policy 
making processes have been highlighted many times by 
policy analysts working in low-income settings13,15,33. Malawi 
offers an interesting, and perhaps rare, case of  policy making 
processes on a single intervention that occurred at two points 
in time, and through two policy making bodies (the NTP or 
the national HIV Unit). Utilising a conceptual framework 
that highlights the importance of  context, evidence and 
networks have illustrated how changes in the nature of  
some of  these elements can affect the roles of  key actors, 
and lead to different policy making processes. In terms of  
the 2002 policy, the context of  the NTP showed that it was 
well funded, with a focus on bio-medical intervention; and 
was specifically looking for a means to reduce deaths among 
TB patients co-infected with HIV. As evidence was lacking 
in areas of  high bacterial resistance to CTX, operational 
research was conducted on the efficacy and feasibility of  
CPT, providing evidence that was particularly relevant 
to influencing policy and change practice. However, this 
research did not provide answers to key areas of  concern 
identified at the policy meeting, namely the potential to create 
cross resistance with SP and whether CPT would be needed 
if  HAART was introduced. With these potential barriers, the 
activities of  a well positioned policy entrepreneur, supported 
by a group of  influential champions, was needed to achieve 
policy change. By 2005, changes in the context and evidence 
base could be seen. The HIV programme was focussing 
on treatment, care and support issues, and evidence on the 
efficacy of  CPT for HIV positive patients in areas of  high 
bacterial resistance to CTX had been gathered. Along with 
the reduction in the reliance on SP, there were no longer 
barriers to the development of  a CPT policy for all HIV 
infected individuals, and no longer a need for an influential 
network to press it forward. The same policy entrepreneur 
was involved in the second policy development process,but 
he played a different role - shifting from bridging the 
researcher and policy making communities, to a much more 
straightforward process of  facilitating discussions about the 
evidence that ultimately led to the adoption of  CPT for a 
much wider group of  patients.
Conclusion
Despite idealised models, there is no simple or single way in 
which evidence gets taken up into policy. Instead, multiple 
factors work together to shape the ways this can be done. In 
the case of  CPT a number of  studies on the drug’s efficacy 
in Africa were published between 1999 and 2005, providing 
several pieces of  evidence on which decisions could be made 
2-3,5,16,18-19,25-26,34. Yet, as numerous authors have pointed out, 
there has been varied and, at times, slow uptake of  CPT 
across African settings7-9. This study has shown how a policy 
analysis lens can provide a powerful lens through which the 
policy change process can be explained and understood. 
Policy decisions are never value-free simple assessments of  
epidemiological evidence, but are a result of  competing ideas, 
and having key actors using evidence to support positions 
they promote. The framework used here to look at context, 
evidence, and links has shown how this played out in Malawi 
over CPT for HIV affected individuals, and can help to guide 
other investigations of  the research to policy process.
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